Patrys Secures 50% Revenue Share in IP Commercialisation
Released
Released
Announcement PDF
1
13 July 2026
PATRYS SECURES 50% REVENUE SHARE IN IP
COMMERCIALISATION DEAL
HIGHLIGHTS
• Binding agreement entered into with the University to support ongoing development and
commercialisation of the deoxymab intellectual property portfolio
• The University has agreed to pay Patrys fifty percent (50%) of all future commercialisation
revenue received by the University directly attributable to the deoxymab intellectual
property portfolio
• Commercialisation revenue includes cash and non-cash considerations, including equity
interests, licensing revenue, royalties, milestone payments and other commercial
transaction consideration
• Transaction structure facilitates focus on advancing and commercialising the deoxymab
platform, and a potential new Yale venture, Nucleicon, founded by deoxymab inventor
James Hansen, MD
• Preserves significant long-term shareholder exposure to future upside while materially
reducing Patrys’ future capital requirements
• Enables ongoing advancement of the deoxymab portfolio through academic research
capabilities and access to specialist external funding pathways
Patrys Limited (ASX: PAB) (Patrys, the Company), is pleased to announce that it has entered into a
binding agreement (Agreement) with Yale University (University) in respect of a revenue sharing
arrangement regarding the deoxymab intellectual property portfolio (Deoxymab IP) (Transaction),
supporting the potential further development and commercialisation of the Deoxymab IP.
The Transaction is designed to maintain Patrys’ participation in the future commercial success of the
deoxymab platform and preserve meaningful long-term shareholder participation in future value
creation, while substantially reducing the Company’s future funding requirements associated with
ongoing development activities.
CEO, Dr Samantha South, said:
“This transaction represents an important strategic milestone for Patrys and the deoxymab platform.
This agreement preserves the Company’s involvement and exposure to potential future commercial
success, while materially reducing the capital required to continue advancing the asset internally.
Importantly, the structure creates a pathway for the deoxymab portfolio to progress within a
University-supported commercialisation framework capable of accessing specialist expertise, strategic
partnerships and external funding opportunities.
We believe this approach provides the best opportunity to maximise long-term value creation for
shareholders while continuing to support advancement of the underlying science.”
2
Nucleicon founder and Deoxymab inventor, Dr James Hansen, said:
“My research career has been dedicated to developing Deoxymab and uncovering its unique
mechanisms of action. I am incredibly excited to now have the opportunity to continue advancing this
transformative antibody towards its full potential as a novel therapeutic that I believe will
fundamentally change how we treat multiple diseases.”
Summary of material terms of the Agreement
Under the terms of the Agreement, the Company will assign the Deoxymab IP to the University, the
University will be responsible (either directly or via third-party funding) for a majority of the future
research and development costs of the Deoxymab IP (except for some ongoing costs that Patrys will
contribute to, as set out below), and Patrys will assign all relevant deoxymab intellectual property
rights and associated assets to the University. This structure is intended to provide a University
supported framework and establish a more capital-efficient and development-focused pathway.
In consideration for assigning the Deoxymab IP to the University, Patrys will be entitled to fifty percent
(50%) of all future commercialisation revenue received by the University that is directly attributable
to the commercialisation of the Deoxymab IP portfolio (including cash and non-cash consideration,
equity interests, licensing income, royalties, milestone payments and other commercial
consideration). This revenue sharing arrangement allows Patrys to retain a meaningful involvement
and substantial long term economic exposure to any future commercial success from the Deoxymab
IP portfolio.
The Transaction provides a pathway for continued development of the Deoxymab IP through a
dedicated commercialisation vehicle supported by academic research capabilities and external
funding opportunities, without requiring the Company to commit significant additional capital or
internal resources to ongoing development activities.
Ongoing Development Activities
It is intended that once the Deoxymab IP is assigned to the University, the University will transfer the
Deoxymab IP into a new start-up entity, with Patrys becoming a direct shareholder in that start-up
entity. This will allow Patrys to maintain an ongoing strategic interest in the Deoxymab IP portfolio,
and ensures Patrys’ continued participation in the future development of the Deoxymab IP portfolio.
To facilitate this structure with the new start-up entity, it is necessary for the Deoxymab IP to be
bundled and assigned to the University prior to being transferred into a university-backed start-up
entity established to further develop the Deoxymab IP.
Furthermore, Patrys will continue supporting ongoing clinical research of the deoxymab program,
through external collaborations, including the ongoing vasculitis pre-clinical research of DX1 and DX3
in collaboration with Dr O’Sullivan at Monash University to support further development and potential
commercialisation of the deoxymab program. This ongoing work is intended to further strengthen the
scientific validation, translational potential and commercial attractiveness of the deoxymab platform
and enhance the value of the Deoxymab IP to be assigned to the University under the Transaction.
The Company notes that commercialisation activities remain subject to ongoing development of the
Deoxymab IP, securing appropriate funding, execution of definitive commercialisation transaction
documents and satisfaction of customary regulatory and operational conditions.
3
Use of Funds
The Company intends to spend funds raised from its April placement (ASX: 20 April 2026), on activities
to advance key value-driving milestones in the Company’s development programs (relating to the
Reliis business, as well as the deoxymab portfolio), including:
Allocation of funds1
AUD
Advancement of RLS-2202 towards clinical development2
$1,981,823
Costs associated with the deoxymab intellectual property portfolio3
$683,344
Working capital4
$534,833
Total $3,200,000
Notes:
1. The above table (and corresponding notes below) sets out the Company’s intentions as at the date of this
announcement. As with any use of funds, intervening events and new circumstances have the potential to affect the
manner in which the funds are ultimately applied, and the Board reserves its right to alter the way funds are applied
on this basis.
2. Includes costs associated with progression into first-in-human Phase 1A clinical trial execution, advancement of
manufacturing and ensuring readiness of drug product for clinical trials, engagement of specialist consultants and
preparing of pre-IND meeting documentation, establishing regulatory and development pathway with the FDA, and
maintenance and advancement of the Company’s intellectual property portfolio.
3. Maintenance and advancement of the Company’s intellectual property portfolio, including approximately $290,000
towards the ongoing maintenance and development of the deoxymab portfolio; $243,344 towards the ongoing pre-
clinical research program with Monash University and $150,000 to be spent towards ongoing costs of the Deoxymab
IP to be assigned to Yale University under the Agreement.
4. Working capital includes costs associated with the Company’s operations, including (but not limited to) staff and
governance costs.
Consideration of ASX Listing Rules 11.1 and 11.2
PAB remains committed to continuing its main undertaking following the Transaction, that being the
development of differentiated, mechanism-based therapies that address acute and chronic immune
inflammatory conditions. The Company will continue to be actively engaged in the development of
the deoxymab portfolio (including, through the Monash program and expenditure on the program, as
set out in the use of funds above). Further, the Transaction does not result in material changes to
PAB’s financial benchmarks of capital structure to the extent that would ordinarily require shareholder
approval under ASX Listing Rule 11.2.
Accordingly, the Company does not consider that the Transaction involves a significant change of
nature or scale in PAB’s main business activities. The Transaction involves an assignment of the
Deoxymab IP back to the University, to establish a more capital-efficient and development-focused
pathway for the advancement of the deoxymab portfolio. PAB considers that the Transaction
facilitates a continuation and evolution of the existing strategy of the deoxymab portfolio, rather than
an endpoint for PAB.
The Company has sought and obtained confirmation from ASX that ASX Listing Rules 11.1 and 11.2 do
not apply to the Transaction, on the basis set out above.
4
-Ends-
This announcement is authorised for release by the Board of Directors of Patrys Limited.
For further information, please contact:
General enquiries
Dr Samantha South
Chief Executive Officer
P: + 61 421 117 241
info@patrys.com
Registered Office Address
168 Stirling Highway
Nedlands WA, 6009
About Patrys Limited
Patrys (ASX:PAB) is a clinical-stage company developing an injectable therapy for delirium alongside a
differentiated deoxymab platform targeting immune-mediated inflammatory diseases. More
information can be found at www.patrys.com.
Forward Looking Statements
This announcement may contain certain “forward-looking statements”. Forward looking statements can
generally be identified by the use of forward-looking words such as, “expect”, “should”, “could”, “may”, “predict”,
“plan”, “will”, “believe”, “forecast”, “estimate”, “target” and other similar expressions. Indications of, and
guidance on, future earnings and financial position and performance are also forward-looking statements.
Forward-looking statements, opinions and estimates provided in this presentation are based on assumptions and
contingencies which are subject to change without notice, as are statements about market and industry trends,
which are based on interpretations of current market conditions. Forward-looking statements including
projections, guidance on future earnings and estimates are provided as a general guide only and should not be
relied upon as an indication or guarantee of future performance.
Share your feedback
Discover